As antibody-drug conjugates (ADCs) and bioconjugates grow increasingly popular across the biopharmaceutical industry, manufacturers must find adaptive solutions to produce them efficiently. As you consider partners to aid in your bioconjugate development journey, look for those that can provide specialized insight into process optimization, scale-up, and process validation.

By Charlotte Sornay, Ph.D., MSAT Associate Principal Scientist in Bioconjugates, Lonza, and Laurence Bonnafoux, Ph.D., Head of MSAT Bioconjugates, Lonza
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content

Latest briefing from the Knowledge Center